pI: 6.683 |
Length (AA): 284 |
MW (Da): 30404 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 8 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 278 | 2br2 (B) | 13 | 234 | 24.00 | 0 | 1 | 1 | -0.14 |
4 | 252 | 2ba0 (F) | 14 | 246 | 22.00 | 0 | 0.63 | 1.1 | -0.07 |
7 | 160 | 2br2 (B) | 19 | 166 | 31.00 | 0.00000000002 | 0.98 | 0.97 | -0.7 |
5 | 256 | 3m7n (D) | 15 | 250 | 23.00 | 0 | 0.97 | 1.12272 | 0.23 |
7 | 206 | 2nn6 (B) | 12 | 206 | 32.00 | 0 | 1 | 0.988825 | 0.67 |
7 | 282 | 1r6l (A) | 3 | 239 | 20.00 | 0 | 1 | 0.929231 | 0.54 |
11 | 250 | 2nn6 (F) | 31 | 247 | 35.00 | 0.00000000022 | 0.98 | 0.86367 | 1.31 |
18 | 157 | 5jea (F) | 45 | 193 | 21.00 | 0.056 | 1 | 0.624358 | -0.3 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | epimastigote, metacyclic. | Smircich P |
Smircich P | Ribosome profiling reveals translation control as a key mechanism generating differential gene expression in Trypanosoma cruzi. |
Ortholog group members (OG5_128693)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G46210 | ribosomal protein S5 domain 2-like superfamily protein |
Brugia malayi | Bm1_42620 | DNA segment, Chr 7, Wayne State University 180, expressed |
Candida albicans | CaO19.81 | similar to S. cerevisiae RRP46 (YGR095C) exosome component involved mRNA degradation and nuclear RNA processing |
Caenorhabditis elegans | CELE_C14A4.5 | Protein CRN-5 |
Cryptosporidium hominis | Chro.40220 | hypothetical protein |
Cryptosporidium parvum | cgd4_1950 | RPR46-like RNAse PH domain |
Dictyostelium discoideum | DDB_G0284053 | hypothetical protein |
Drosophila melanogaster | Dmel_CG4043 | CG4043 gene product from transcript CG4043-RA |
Echinococcus granulosus | EgrG_001137700 | exosome complex exonuclease RRP46 |
Entamoeba histolytica | EHI_086520 | 3 exoribonuclease family protein |
Echinococcus multilocularis | EmuJ_001137700 | exosome complex exonuclease RRP46 |
Giardia lamblia | GL50803_1890 | 3 exoribonuclease, putative |
Homo sapiens | ENSG00000077348 | exosome component 5 |
Leishmania donovani | LdBPK_020290.1 | ribosomal RNA processing protein 41B, putative |
Leishmania infantum | LinJ.02.0290 | ribosomal RNA processing protein, putative |
Leishmania major | LmjF.02.0320 | ribosomal RNA processing protein, putative |
Leishmania mexicana | LmxM.02.0320 | ribosomal RNA processing protein, putative |
Loa Loa (eye worm) | LOAG_03684 | hypothetical protein |
Mus musculus | ENSMUSG00000061286 | exosome component 5 |
Neospora caninum | NCLIV_044790 | 3 exoribonuclease family, domain 1 containing protein, putative |
Oryza sativa | 4334824 | Os03g0854200 |
Saccharomyces cerevisiae | YGR095C | Rrp46p |
Schistosoma japonicum | Sjp_0028190 | expressed protein |
Schistosoma mansoni | Smp_056900 | ribonuclease pH related |
Schmidtea mediterranea | mk4.001849.03 | Ribonuclease pH related |
Trypanosoma brucei gambiense | Tbg.972.2.740 | ribosomal RNA processing protein 41B,RNase PH-like protein,exosome complex exonuclease 1 |
Trypanosoma brucei | Tb927.2.2180 | ribosomal RNA processing protein 41B |
Trypanosoma congolense | TcIL3000_0_54840 | ribosomal RNA processing protein 41B, putative |
Trypanosoma cruzi | TcCLB.503653.30 | RNase PH-like protein, putative |
Trypanosoma cruzi | TcCLB.505037.20 | ribosomal RNA processing protein 41B, putative |
Toxoplasma gondii | TGME49_306610 | 3' exoribonuclease family, domain 1 domain-containing protein |
Trichomonas vaginalis | TVAG_287740 | Exosome complex exonuclease RRP46, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.2.2180 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.2.2180 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.2.2180 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.2.2180 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C14A4.5 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C14A4.5 | Caenorhabditis elegans | slow growth | wormbase |
YGR095C | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_306610 | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.